Membranous Nephropathy: Quantifying Remission Duration on Outcome.
about
Treatment of membranous nephropathy: time for a paradigm shift.Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy.miR-217 Is a Useful Diagnostic Biomarker and Regulates Human Podocyte Cells Apoptosis via Targeting TNFSF11 in Membranous Nephropathy.Clinical implications of pathological features of primary membranous nephropathy
P2860
Membranous Nephropathy: Quantifying Remission Duration on Outcome.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Membranous Nephropathy: Quantifying Remission Duration on Outcome.
@ast
Membranous Nephropathy: Quantifying Remission Duration on Outcome.
@en
type
label
Membranous Nephropathy: Quantifying Remission Duration on Outcome.
@ast
Membranous Nephropathy: Quantifying Remission Duration on Outcome.
@en
prefLabel
Membranous Nephropathy: Quantifying Remission Duration on Outcome.
@ast
Membranous Nephropathy: Quantifying Remission Duration on Outcome.
@en
P2093
P2860
P356
P1476
Membranous Nephropathy: Quantifying Remission Duration on Outcome.
@en
P2093
Daniel C Cattran
Esther D Kim
Heather Reich
Michelle Hladunewich
S Joseph Kim
Toronto Glomerulonephritis Registry group
P2860
P304
P356
10.1681/ASN.2015111262
P577
2016-10-18T00:00:00Z